Netmore Group and Stena Fastigheter Collaborate to Connect 27,000 Apartments with LoRaWAN Technology
Netmore Group, a leading global LoRaWAN network operator, has entered into a agreement with Stena Fastigheter, a Swedish real estate company to implement LoRaWAN technology across Stena’s property portfolio. This initiative aims to enhance energy efficiency and digital capabilities of Stena's real estate operations.
Project scope and implementation
The project involves providing Netmore’s LoRaWAN connectivity to apartments across Stockholm, Malmö, and Gothenburg. The implementation includes the installation of a large number of LoRaWAN gateways to support Stena’s rollout of submetering (IMD) and temperature/humidity sensors, including up to approximately 42,900 meters and sensors.
Initial focus on energy optimization and enhanced quality of living
A key aspect of the partnership is the use of technology for energy optimization. The primary applications include sub-metering enabled by the deployment of water meters, along with temperature and humidity sensors, which are expected to contribute to more efficient energy management in Stena's properties. Additionally, this technological integration is anticipated to enhance the quality of living for residents, offering a more comfortable and sustainable living environment.
Eric Collinder, Country Manager Nordics at Netmore Group, stated, "We are now entering a phase where LoRaWAN becomes the natural choice of access technology for property owners. We are particularly proud to have Stena Fastigheter, a leading property company in the Nordics, as our customer. They are a prime example of this, opting to equip their portfolio with Netmore LoRaWAN. Providing connectivity for solutions of this scale aligns well with our strategic goals and reflects our established expertise in the property sector.”
Peter Mikulic, Head of Digital Transformation at Stena Fastigheter, expressed, "By equipping our properties with meters and sensors, we can constantly align with the consumption patterns of the buildings and the needs of our tenants, while ensuring that any excess consumption is minimized. After a thorough evaluation of various access technologies and connectivity providers, we chose Netmore LoRaWAN. With Netmore’s connectivity, we can continue to maintain the high level of innovation and environmental consideration that our tenants have come to associate with us.”
Potential for future technological integration
While the initial focus is on energy optimization, the partnership and LoRaWAN technology also allows for the exploration and deployment of additional technological applications in real estate management in the future, demonstrating the versatility of Netmore's LoRaWAN solutions.
Potential applications include:
- Water Leak Detection: Sensors to identify and alert about water leaks, preventing damage and conserving water.
- HVAC System Monitoring: Advanced monitoring and control of heating, ventilation, and air conditioning systems for optimal energy use and resident comfort.
- Waste Management Optimization: Intelligent waste collection solutions to optimize resource use and reduce environmental impact.
- Smoke Detection: Deployment of smoke detectors for enhanced safety and rapid response in case of fire.
- Radon Measurement: Utilization of radon measuring devices to monitor and ensure healthy indoor air quality.
Effortlessly connect your property portfolio to Netmore LoRaWAN
Netmore, in collaboration with property owners and application developers, has developed a streamlined, reliable, and cost-effective LoRaWAN offering that enables scalable deployment of sensor networks in both individual properties and extensive property portfolios throughout Europe. Property owners gain several advantages with Netmore LoRaWAN:
- Efficient and Rapid Deployment of Large-Scale Sensor Projects: Property owners can quickly and easily set up expansive sensor networks.
- Professionally Monitored Dedicated Network: As the operator, Netmore provides property owners with their own network, which is professionally monitored and maintained.
- Open and Future-Proof Network: The network allows for a wide range of valuable and useful digitalization applications, ensuring longevity and adaptability for future needs.
- Access to Netmore Market: Property owners can access a comprehensive range of turnkey digitalization solutions specifically designed for real estate through the Netmore Market.
- Comprehensive Coverage within Properties: With Netmore LoRaWAN, property owners can reach all measurement points, regardless of their location within the property.
- Extended Sensor Battery Life: LoRaWAN technology enables up to 15 years of battery life per sensor, significantly reducing maintenance and replacement needs.
For more information about Netmore’s solutions for smarter and more resource efficient properties and buildings, visit: LoRaWAN for Properties.
About Stena
Stena Fastigheter is one of Sweden's largest private real estate companies with more than 27,000 apartments and around 2,500 commercial objects in the metropolitan areas in Sweden. Internationally the operations are conducted by Stena Real Estate. Sustainability is high on the agenda and through the relationship management approach, we develop our neighbourhoods together with the residents and other stakeholders to create attractive areas where people thrive and stay for a long time.
About Netmore Group
Netmore Group is an IoT network operator, building the leading multinational network to advance sustainable business practices. We offer a reliable network platform and leading connectivity expertise for efficient measuring, monitoring, and optimisation of resource use. With 10 years in the industry, we have a solid track record, operating borderless on the European market and have grown to become a leading global network operator. Netmore group’s main owner is the Nordic infrastructure investor Polar Structure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240616361213/en/
Contacts
Media Contact:
James Gerber
Crackle Communications
+1 508-233-3391
netmore@cracklepr.com
Netmore Contact:
Ken Lynch
VP, Global Marketing
+1 617-877-5393
ken.lynch@netmoregroup.com
Stena Fastigheter Contact:
Peter Mikulic, Head of Digital Transformation, Stena Fastigheter
Phone: + +46101675037
E-mail: peter.mikulic@stena.com
LinkedIn: https://www.linkedin.com/in/petermikulic/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.c
om%2Fin%2Fpetermikulic%2F&esheet=54062369&newsitemid=20240616361213&lan=en-US&an
chor=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fpetermikulic%2F&index=3&md5=6a8a28861
051c3c4a884f07d9ff821fd
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press Release
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S.2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patient
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press Release
Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unlike other issues facing financial services companies, fraud operates b
Capcom Announces Onimusha Way of the Sword , Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press Release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press Release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom